Tech Company Financing Transactions

Centivax Funding Round

Centivax, based in San Francisco, raised $45 million from private investors, Amplify Partners and Bold Capital Partners.

Transaction Overview

Company Name
Announced On
7/9/2025
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to accelerate its first clinical candidate, a universal flu vaccine currently in CMC development, through a Phase I clinical trial slated to begin within eight months.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Boulevard South
San Francisco, CA 94080
USA
Phone
Undisclosed
Email Address
Overview
Developer of a therapeutics and clinical-stage company intended to treat and eradicate rapidly mutating pathogens. The company applies its computational immune engineering expertise to develop therapeutic monoclonal antibodies against a variety of targets, it builds a panel of neutralizing antibodies against SARS-CoV-2, enabling people to be safe from health issues with the help of vaccinations.
Profile
Centivax LinkedIn Company Profile
Social Media
Centivax Company Twitter Account
Company News
Centivax News
Facebook
Centivax on Facebook
YouTube
Centivax on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jacob Glanville
  Jacob Glanville LinkedIn Profile  Jacob Glanville Twitter Account  Jacob Glanville News  Jacob Glanville on Facebook
Chief Operating Officer
David Tsao
  David Tsao LinkedIn Profile  David Tsao Twitter Account  David Tsao News  David Tsao on Facebook
Chief Technical Officer
Nicholas Bayless
  Nicholas Bayless LinkedIn Profile  Nicholas Bayless Twitter Account  Nicholas Bayless News  Nicholas Bayless on Facebook
Co-Founder
Sawsan Youssef
  Sawsan Youssef LinkedIn Profile  Sawsan Youssef Twitter Account  Sawsan Youssef News  Sawsan Youssef on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/9/2025: Vytalize Health venture capital transaction
Next: 7/9/2025: OllyGarden venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary